Aveo Pharmaceuticals (AVEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2013 | 09-2013 | 06-2013 | 03-2013 | 12-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 51,424 | 50,420 | 33,822 | 85,898 | 76,134 |
| Marketable Securities | 67,680 | 79,942 | 122,348 | 105,736 | 84,468 |
| Receivables | 6,817 | 8,893 | 7,897 | 9,181 | 23,889 |
| TOTAL | $128,919 | $146,487 | $173,284 | $210,559 | $190,681 |
| Non-Current Assets | |||||
| PPE Net | 14,140 | 12,766 | 13,238 | 13,331 | 12,867 |
| Other Non-Current Assets | 3,287 | 3,861 | 3,888 | 3,925 | 3,921 |
| TOTAL | $17,427 | $16,627 | $17,126 | $17,256 | $16,788 |
| Total Assets | $146,346 | $163,114 | $190,410 | $227,815 | $207,469 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,238 | 6,137 | 7,230 | 8,083 | 10,628 |
| Accrued Expenses | 13,263 | 12,154 | 14,314 | 18,067 | 19,543 |
| Other current liabilities | 1,238 | 1,238 | 1,238 | N/A | N/A |
| TOTAL | $31,408 | $31,730 | $34,688 | $37,746 | $39,130 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,822 | 11,549 | 14,184 | 16,731 | 19,228 |
| Deferred Revenues | 2,286 | 2,158 | 2,197 | 2,212 | 2,150 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1,238 | 1,238 |
| TOTAL | $45,000 | $45,574 | $46,816 | $48,887 | $49,401 |
| Total Liabilities | $76,408 | $77,304 | $81,504 | $86,633 | $88,531 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 5,179 | 5,186 | 5,217 | 5,189 | 5,184 |
| Common Shares | 52 | 52 | 52 | 52 | 44 |
| Retained earnings | -427,289 | -410,564 | -386,258 | -354,345 | -320,260 |
| Other shareholders' equity | -2 | 8 | -35 | 14 | -19 |
| TOTAL | $69,938 | $85,810 | $108,906 | $141,182 | $118,938 |
| Total Liabilities And Equity | $146,346 | $163,114 | $190,410 | $227,815 | $207,469 |